DarioHealth Q2 Loss Widens to $12.12M Despite 18.5% Revenue Jump

Ticker: DRIO · Form: 10-Q · Filed: Aug 12, 2025 · CIK: 1533998

Dariohealth CORP. 10-Q Filing Summary
FieldDetail
CompanyDariohealth CORP. (DRIO)
Form Type10-Q
Filed DateAug 12, 2025
Risk Levelhigh
Pages15
Reading Time18 min
Key Dollar Amounts$0.0001, $1
Sentimentbearish

Sentiment: bearish

Topics: Digital Health, Net Loss, Revenue Growth, Dilution Risk, SEC Filing, 10-Q, Healthcare Technology

Related Tickers: DRIO

TL;DR

**DRIO's revenue growth is overshadowed by ballooning losses; steer clear until they show a path to profitability.**

AI Summary

DarioHealth Corp. reported a net loss of $12.12 million for the quarter ended June 30, 2025, a significant increase from the $10.47 million net loss in the prior-year quarter. Revenue for the three months ended June 30, 2025, was $4.55 million, up from $3.84 million in the same period of 2024, representing an 18.5% increase. The company's strategic outlook includes continued investment in its digital health platform, evidenced by the issuance of Series D-2 and Series D-3 Preferred Stock on January 7, 2025, as part of a Series D Purchase Agreement. Key business changes include the issuance of 45,474,935 shares of common stock during the quarter ended June 30, 2025, impacting shareholder dilution. Risks include ongoing net losses and the need for additional capital, as reflected by the $12.12 million accumulated deficit. The company also granted performance-based stock options under its 2020 Plan during June 2025, aligning executive incentives with future performance.

Why It Matters

DarioHealth's widening net loss to $12.12 million, despite an 18.5% revenue increase to $4.55 million, signals a critical juncture for investors. The continued burn rate and reliance on preferred stock issuances, like the Series D-2 and D-3 on January 7, 2025, raise questions about long-term financial sustainability and potential further dilution for common shareholders. In a competitive digital health market, DRIO's ability to translate revenue growth into profitability is paramount, impacting its capacity to innovate and retain customers against larger, more established players. Employees and customers will be watching for signs of financial stability to ensure continued service and job security.

Risk Assessment

Risk Level: high — The company reported a net loss of $12.12 million for the quarter ended June 30, 2025, an increase from $10.47 million in the prior-year quarter, indicating a worsening financial performance. The accumulated deficit of $454.75 million as of June 30, 2025, compared to $383.88 million as of June 30, 2024, highlights significant ongoing losses and a substantial need for future capital.

Analyst Insight

Investors should exercise extreme caution and consider avoiding DRIO stock until the company demonstrates a clear and viable path to profitability. Monitor future filings for evidence of reduced net losses and improved cash flow, as the current trend of increasing losses despite revenue growth is unsustainable.

Financial Highlights

revenue
$4.55M
net Income
-$12.12M
revenue Growth
+18.5%

Key Numbers

Key Players & Entities

FAQ

What were DarioHealth Corp.'s key financial results for Q2 2025?

DarioHealth Corp. reported a net loss of $12.12 million for the quarter ended June 30, 2025, compared to a net loss of $10.47 million in the prior-year quarter. Revenue increased by 18.5% to $4.55 million for Q2 2025, up from $3.84 million in Q2 2024.

How has DarioHealth's accumulated deficit changed?

DarioHealth's accumulated deficit increased to $454.75 million as of June 30, 2025, from $383.88 million as of June 30, 2024, reflecting continued operational losses.

What strategic financing activities did DarioHealth undertake in early 2025?

On January 7, 2025, DarioHealth entered into a Series D Purchase Agreement, which included the issuance of Series D-2 and Series D-3 Preferred Stock, indicating efforts to secure additional capital.

What is the risk level associated with investing in DarioHealth based on this 10-Q?

The risk level is high due to the widening net loss of $12.12 million and the substantial accumulated deficit of $454.75 million, indicating ongoing financial challenges and a need for further capital.

How many shares of common stock did DarioHealth issue in Q2 2025?

DarioHealth issued 45,474,935 shares of common stock during the quarter ended June 30, 2025, which could lead to shareholder dilution.

What is the significance of the 2020 Plan for DarioHealth employees?

The 2020 Plan is used for granting performance-based stock options to employees and consultants, with grants occurring in June 2025, aligning incentives with company performance.

What should investors consider regarding DarioHealth's revenue growth?

While DarioHealth's revenue grew by 18.5% to $4.55 million, investors should note that this growth has not yet translated into profitability, as net losses continue to widen.

What is DarioHealth's business address?

DarioHealth Corp.'s business address is 322 W 57th St. #33B, New York, NY 10019.

When was DarioHealth Corp. formerly known as LabStyle Innovations Corp.?

DarioHealth Corp. changed its name from LabStyle Innovations Corp. on November 1, 2011.

What is DarioHealth's primary industry classification?

DarioHealth Corp. is classified under Surgical & Medical Instruments & Apparatus [3841].

Risk Factors

Industry Context

The digital health market is experiencing rapid growth, driven by technological advancements, increased consumer adoption of remote care solutions, and a focus on preventative health. Companies like DarioHealth operate in a competitive landscape that includes established healthcare providers, technology giants, and numerous startups vying for market share.

Regulatory Implications

As a digital health company, DarioHealth is subject to various regulations concerning data privacy (e.g., HIPAA in the US), medical device approvals, and healthcare reimbursement policies. Changes in these regulations or non-compliance can significantly impact operations and financial performance.

What Investors Should Do

  1. Monitor the company's ability to convert revenue growth into profitability, given the increasing net loss.
  2. Assess the impact of the significant common stock issuance on shareholder value and future earnings per share.
  3. Evaluate the progress and market adoption of DarioHealth's digital health platform investments.
  4. Consider the company's ongoing need for capital and its ability to secure future funding rounds.

Key Dates

Glossary

Accumulated Deficit
The total cumulative net losses of a company since its inception, less any cumulative net income. (Indicates the company's historical profitability, with DarioHealth's deficit at $454.75 million as of June 30, 2025.)
Series D-2 and Series D-3 Preferred Stock
Specific classes of preferred stock issued as part of a larger financing round (Series D Purchase Agreement). (Represents a key financing activity in early 2025, crucial for funding the company's operations and growth initiatives.)
Performance-Based Stock Options
Stock options granted to employees or executives that vest or become exercisable only upon the achievement of specific performance targets. (Demonstrates a strategy to incentivize management and align their interests with the company's future success, as seen with grants under the 2020 Plan in June 2025.)
Common Stock Issued
The number of shares of common stock that have been issued by the company. (A significant issuance of 45,474,935 shares in Q2 2025 highlights potential dilution for existing shareholders.)

Year-Over-Year Comparison

Compared to the prior-year quarter, DarioHealth demonstrated strong top-line growth with an 18.5% increase in revenue to $4.55 million. However, this growth was accompanied by a widening net loss, which increased from $10.47 million to $12.12 million. The accumulated deficit also grew significantly, underscoring the continued challenge of achieving profitability. A notable event this quarter was the issuance of over 45 million shares of common stock, a factor that investors should consider regarding potential dilution.

Filing Stats: 4,460 words · 18 min read · ~15 pages · Grade level 15.4 · Accepted 2025-08-12 06:06:00

Key Financial Figures

Filing Documents

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 4 Item 4. Control and Procedures 15

- OTHER INFORMATION

PART II - OTHER INFORMATION 17 Item 1A.

Risk Factors

Risk Factors 17 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 21 Item 5 . Other Information. 21 Item 6. Exhibits 22

SIGNATURES

SIGNATURES 23 2 Table of Contents CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Certain information set forth in this Quarterly Report on Form 10-Q, including in Item 2, "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere herein may address or relate to future events and expectations and as such constitutes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements which are not historical reflect our current expectations and projections about our future results, performance, liquidity, financial condition, prospects and opportunities and are based upon information currently available to us and our management and their interpretation of what is believed to be significant factors affecting our business, including many assumptions regarding future events. Such forward-looking statements include statements regarding, among other things: our current and future capital requirements and our ability to satisfy our capital needs through financing transactions or otherwise; our ability to meet the requirements of our existing debt facility; our product launches and market penetration plans; the execution of agreements with various providers for our solution; our ability to maintain our relationships with key partners; our ability to complete required clinical trials of our product and obtain clearance or approval from the United States Food and Drug Administration (the "FDA"), or other regulatory agencies in different jurisdictions; our ability to maintain or protect the validity of our U.S. and other patents and other intellectual property; our ability to retain key executive members; our ability to internally develop new inventions and intellectual property; that our financial position raises substantial doubt about our ability to continue as a going concern; general market, political and economic conditions in the countries in which we operat

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing